
0:41
A short YouTube commentary by Dr. Charles Mok about the neuromodulator product Daxify. The speaker challenges Daxify's marketed six-month duration, stating it actually lasts six months in roughly 47% of people, requires about twice the units versus Botox/Xeomin, and is more expensive — arguing that an approximately four-month duration represents the best value given dose–duration tradeoffs.










